SUMMARY
INTRODUCTION
Tuberculosis case notification rates (CNR) among gold miners in South Africa are very high, exceeding 4000/100000 in 1999 [1] , compared with 960/100000 nationally in South Africa in 2008 [2] , attributable to high prevalence of HIV (29% in 2001) and silicosis [3, 4] . In the 1990s, the proportion of tuberculosis episodes with multi-drug resistance was stable and relatively low in miners [5, 6] , estimated at 1.0% and 2.8% among previously untreated and previously treated episodes respectively [5] . More recently in South Africa, transmission of drug-resistant tuberculosis and resistance to second line antituberculous agents has been reported in association with HIV treatment facilities [7] and gold miners [8] .
The aims of this study were: 1) to describe trends in CNR and prevalence of drug resistance among tuberculosis episodes from 2002-8; 2) to analyse the effect of previous tuberculosis treatment and HIV infection on drug resistance in a gold mining workforce, in a period preceding a large-scale tuberculosis prevention intervention.
STUDY POPULATION AND METHODS
We analysed routine data from 2002-8 in two mining companies in Gauteng province, South Africa (companies A and B). From 2006, companies participated in "Thibela TB", a clusterrandomised trial of community-wide isoniazid preventive therapy (IPT) [9] . Of seven mine shafts contributing data for this analysis, two were intervention (starting June and July 2007) and five control clusters. Policy in both companies from 2002-8 was to perform culture and DST for rifampicin and isoniazid routinely for retreatment cases and cases responding poorly to treatment.
Company A also routinely tested previously untreated cases. Second-line DST was only performed among multi-drug resistant tuberculosis (MDRTB) episodes after 2006. Medical records (electronic where available, supplemented by paper records), laboratory records and tuberculosis registers were reviewed retrospectively. For paper-based source data, for logistic reasons, complete data were only extracted for episodes with DST results.
Definitions
The CNR was defined as the number of tuberculosis treatment episodes recorded in the tuberculosis register during a given period of time, per 100000 population, with denominators calculated as below (see "data analysis").
HIV status was defined as positive if a positive rapid test or ELISA result was recorded before tuberculosis treatment was started or up to six months afterwards, and negative if a negative result was recorded after the start of tuberculosis treatment or up to six months before.
Drug resistance in previously untreated versus previously treated cases was defined as drug-resistant tuberculosis occurring in an individual with fewer than 30 versus 30 or more days previous tuberculosis treatment exposure. Changes in drug susceptibility during treatment were also counted as episodes of drug resistance in previously treated cases and included in calculating CNR for drug-resistant tuberculosis and prevalence ratios for drug resistance by treatment history and HIV status.
MDRTB was defined as M. tuberculosis resistant to at least rifampicin and isoniazid.
Rifampicin and isoniazid monoresistance were defined as M. tuberculosis resistant to rifampicin but not isoniazid and isoniazid but not rifampicin, respectively.
Data analysis
In order to avoid counting re-registrations of the same tuberculosis disease episode, which 
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Trends in drug resistance among previously untreated cases
In company A, the proportion of previously untreated cases with MDRTB rose from 2/245 Comparisons with South African national rates must consider the denominator population of a workforce with strong tuberculosis risk factors.
Second-line DST
Despite CNR decreasing overall, MDRTB CNR in company A increased. Although several factors may be contributory, including artefact due to higher DST coverage, we consider this to be unlikely to account for all the increase in MDRTB CNR seen here; which is more likely to be a true increase as rifampicin resistance is superimposed on existing isoniazid resistance. Isoniazid monoresistance CNR changed by year in company A, but without evidence of linear increase in either company. Previous studies suggest that rifampicin levels are reduced among HIV-infected individuals [11] and that individual pharmacokinetic variability accounts for some rifampicin resistance [12] . Drugs used in mine health services are obtained from approved national sources and rifampicin under-dosing is unlikely. We do not have data on treatment adherence in this population but are not aware of any factors that may have caused it to change with time.
Proportions with rifampicin-and multi-drug resistance are higher than reported previously in similar populations [5, 6] . Such resistance was associated with previous treatment exposure, consistent with acquisition of resistance due to previous inadequate treatment, as seen in a similar workforce [13] . However, two studies using genotyping, one in a mining population, suggest that circulating MDR strains are also transmitted among previously treated individuals [8, 14] and this will account for a proportion of the resistance seen here.
HIV infection was not a strong risk factor for drug resistance. A South African national survey in 2001-2 suggested some association between HIV infection and MDRTB in previously treated cases [15] . Similarly for rifampicin monoresistance, these results do not exclude an effect of HIV infection among previously treated cases, but numbers are insufficient to conclude that observations are not due to chance. International data, collated in a systematic review, were also inconclusive on this point [16] .
There is inherent uncertainty regarding population CNRs of drug-resistant disease in this observational study as numerators are relatively small. Bias cannot be excluded due to suboptimal DST coverage. DST may have been more likely to be performed when resistance was suspected, resulting in overestimation of observed proportions, where DST was not done systematically. It is unlikely that changes in proportions with MDRTB are entirely due to changes in testing coverage as our data show increased DST coverage over the study period, which may reflect less selective, more routine testing, or possibly an increase in proportions with suspected drug resistance.
HIV status was not documented for all episodes notified, but HIV prevalence among episodes with known status was very high throughout the study period. Strategies for improved HIV testing and treatment coverage are essential to reduce risk of tuberculosis [17] , particularly in view of recent evidence [18, 19, 20] and revised World Health
Organization recommendations for early antiretroviral therapy for all HIV-infected individuals with active tuberculosis [21] . This is particularly important for those with drug-resistant tuberculosis and HIV, among whom mortality is high [22, 23, 24] .
This study was conducted in a period preceding widespread IPT. There has been concern that IPT may lead to increased isoniazid resistance, although there is no evidence for this [25, 26] . Considering that the intervention began in parts of this workforce from June 2007, the period of this analysis is likely to be too early to reflect its impact. Furthermore, IPT is unlikely to have resulted in the increase in MDRTB seen here and there was no evidence of increasing isoniazid monoresistance. Total includes all retreatment episodes, plus 9 changes in DST during treatment of first tuberculosis episodes and 58 first treatment episodes for which DST was done on specimens taken after 30 or more days' treatment exposure 
CONCLUSIONS
